ライフサイエンスコーパス: adrenoceptor

1 ceptor (1000-fold selectivity over the beta1-adrenoceptor).

2 does not occur in the closely related beta2-adrenoceptor.

3 of such shape-shifting system as the beta(2)-adrenoceptor.

4 SAT and very little expression of the beta3-adrenoceptor.

5 protein-coupled receptors such as the beta2-adrenoceptor.

6 angiotensin II type 1 receptor and the beta2 adrenoceptor.

7 e antagonists/inverse agonists of the alpha2-adrenoceptor.

8 to contain the highest densities of alpha2C adrenoceptors.

9 lamus, regions with low densities of alpha2C adrenoceptors.

10 otracer for in vivo imaging of brain alpha2C adrenoceptors.

11 macrophages, which was independent of alpha1 adrenoceptors.

12 orepinephrine inhibits outgrowth via beta(1)-adrenoceptors.

13 ts antagonistic effects on presynaptic beta1-adrenoceptors.

14 D -8.95) and is very selective for the beta2-adrenoceptor (1000-fold selectivity over the beta1-adren

15 e other two subtypes difficult and the beta3-adrenoceptor a less-understood subtype.

16 onflicting functional activity at the alpha2-adrenoceptor, a G-protein-coupled receptor with relevanc

17 s) to directly probe activation of the beta2-adrenoceptor, a prototypical GPCR, and its cognate G pro

18 we decipher the ascending circuitry linking adrenoceptor-activated sacral CPGs and lumbar flexor mot

19 e chronotropic effect on top of maximal beta-adrenoceptor activation in healthy mice.

20 e chronotropic effect on top of maximal beta-adrenoceptor activation in healthy mice.

21 dy investigated the hypothesis that alpha(2)-adrenoceptor activation inhibits icilin-induced WDS.

22 These results suggest that alpha(2)-adrenoceptor activation inhibits shaking induced by icil

23 Instead, beta2 adrenoceptor activation was responsible for mediating ge

24 so found that antagonism of hippocampal beta-adrenoceptor activity with local infusions of propranolo

25 ion variant of the gene encoding the alpha2b-adrenoceptor (ADRA2B), which has been linked to emotiona

26 Regional infusions of beta(2)-adrenoceptor (ADRB2) agonist have generally shown that i

27 ietary sodium affects function of the beta-2 adrenoceptor (ADRB2).

28 epatic progenitor/oval cells (HPCs) and beta-adrenoceptor agonism will expand HPCs to reduce AILI.

29 ill inevitably be taking a long-acting beta2-adrenoceptor agonist (LABA)/ICS combination therapy, we

30 e have further characterized the novel beta2 adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benzyloxyc

31 y intra-BAT injections of the specific beta3-adrenoceptor agonist CL316,243 in one pad and the vehicl

32 xidase (MAO) inhibitor harmane, the alpha(2)-adrenoceptor agonist clonidine, the mu-opioid receptor a

33 nd coronary perfusion during CPR via alpha-1-adrenoceptor agonist effects.

34 ed using multiple concentrations of the beta-adrenoceptor agonist isoproterenol (ISO) and by varying

35 ociation rate we have observed for any beta2 adrenoceptor agonist tested to date.

36 after 2 min of phenylephrine (PE; an alpha1 -adrenoceptor agonist) infusion via brachial artery cathe

37 erial infusion of phenylephrine (PE; alpha1 -adrenoceptor agonist) were calculated during (1) infusio

38 e dexmedetomidine, a highly selective alpha2 adrenoceptor agonist, could safely decrease the incidenc

39 d with APAP (350 mg/kg) followed by the beta-adrenoceptor agonist, isoproterenol (ISO), or the beta-a

40 f 0.3 M NaCl after sc injections of the beta-adrenoceptor agonist, isoproterenol, a hypotensive drug

41 ment with a peripherally restricted alpha(2)-adrenoceptor agonist, ST91 (0.075, 0.15 mg/kg), also dec

42 Cold- and beta3-adrenoceptor agonist-induced sympathetic activation lead

43 combinations (with the Y4 receptor or beta2-adrenoceptor), agonist and antagonist pharmacology was e

44 significantly enhanced by long-acting beta2-adrenoceptor agonists (LABAs) and may contribute to the

45 inetics of several clinically relevant beta2-adrenoceptor agonists and antagonists and demonstrated t

46 am cAMP/PKA signaling attenuated, while beta-adrenoceptor agonists and cAMP/PKA activators enhanced,

47 s that are currently available such as beta2-adrenoceptor agonists and corticosteroids, it takes litt

48 with limited clinical experience, are beta3 adrenoceptor agonists and phosphodiesterase type 5 inhib

49 PD therapy involving anticholinergics, beta2-adrenoceptor agonists and/or corticosteroids, do not spe

50 Muscarinic receptor antagonists and beta-adrenoceptor agonists are used in the treatment of obstr

51 The beta2 adrenoceptor agonists formoterol and salbutamol mediated

52 n the neonatal exposure model, whereas beta2-adrenoceptor agonists had no such effect.

53 inone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and evaluated f

54 beta3-Adrenoceptor agonists have recently been introduced for

55 cal trial study show the efficacy of alpha-2 adrenoceptor agonists in decreasing stress-induced drug

56 of novel, potent, and selective human beta2 adrenoceptor agonists incorporating a sulfone moiety on

57 atecholamine surrogates present in the beta2-adrenoceptor agonists procaterol and BI-167107 (4), we d

58 mically and pharmacodynamically diverse beta-adrenoceptor agonists, isoproterenol and salmeterol.

59 of muscarinic receptor antagonists and beta-adrenoceptor agonists, the full value of such combinatio

60 voked in the finger by alpha(1)- or alpha(2)-adrenoceptor agonists.

61 ve to a series of clinical reference beta(2)-adrenoceptor agonists.

62 Recent progress in structural data of beta-adrenoceptors allows us to understand and predict key in

63 but no more than single knockout of alpha1A-adrenoceptors alone.

64 nd serotonin (5-HT) receptors, we found that adrenoceptor alpha 2C (Adra2c) and serotonin receptor 2a

65 cific heteromerization between the alpha(1A)-adrenoceptor (alpha(1A)AR) and CXC chemokine receptor 2

66 crystal structure, we modeled the alpha(1B)-adrenoceptor (alpha(1B)-AR) to help identify the alloste

67 of prolonged stimulation of MOR on alpha(2)-adrenoceptor (alpha(2)-AR) function.

68 e actions of noradrenaline at spinal alpha2 -adrenoceptors, although serotonin, acting on facilitator

69 Activation of the beta2-adrenoceptor and cannabinoid CB2 receptors can inhibit s

70 High levels of noradrenergic alpha1-adrenoceptor and dopaminergic D1 receptor stimulation ac

71 Both alpha1-adrenoceptor and mineralocorticoid receptor expressions

72 , at a locus between the membrane-bound beta-adrenoceptor and the intracellular cAMP formation site.

73 discovered much later than beta1- and beta2-adrenoceptors and exhibits unique properties which make

74 ed with altered signal transduction via beta-adrenoceptors and G proteins and with reduced cAMP forma

75 osteric inhibitor pharmacophore for alpha(1)-adrenoceptors and mechanistic insight and a new set of s

76 iction or on activation of alpha1- and beta1-adrenoceptors and miR-212/132 led to repression of MeCP2

77 uperoxide production that stimulates alpha2C-adrenoceptors and Rho-kinase-mediated MLC phosphorylatio

78 ha1A-adrenergic G protein-coupled receptors (adrenoceptors) and P2X1-purinoceptor ligand gated ion ch

79 -32), dopamine receptors-1 and -2, alpha-2C- adrenoceptor, and striatally enriched protein tyrosine p

80 nd beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors, and receptors with single-point mutations

81 The beta1-adrenoceptor antagonist 1-[2-((3-Carbamoyl-4-hydroxy)phe

82 by intrathecal administration of the alpha2-adrenoceptor antagonist idazoxan and intra-LC co-injecti

83 ntagonist propranolol, the mixed alpha-/beta-adrenoceptor antagonist labetalol, and the alpha1-adreno

84 oceptor antagonist labetalol, and the alpha1-adrenoceptor antagonist prazosin.

85 that the administration of the beta1-, beta2-adrenoceptor antagonist propranolol decreases cardiac wo

86 mia was significantly attenuated by the beta-adrenoceptor antagonist propranolol, the mixed alpha-/be

87 The alpha(1) adrenoceptor antagonist WB4101, alpha(2) adrenoceptor an

88 eted for hypertension as a nonselective beta-adrenoceptor antagonist with alpha(1)AR antagonist prope

89 (1) adrenoceptor antagonist WB4101, alpha(2) adrenoceptor antagonist yohimbine and mu-opioid receptor

90 were administered hydrocortisone, the alpha2-adrenoceptor antagonist yohimbine, or both before they w

91 athecal administration of yohimbine (alpha-2-adrenoceptor antagonist).

92 luated LK 204-545 (1), (1) a selective beta1-adrenoceptor antagonist, and discovered it possessed sig

93 drenergic tone using atipamezole, an alpha-2 adrenoceptor antagonist, could induce a long-term improv

94 Prazosin, a potent and selective alpha1-adrenoceptor antagonist, displaces 25% of (11)C-CUMI-101

95 ted that (11)C-yohimbine, a selective alpha2-adrenoceptor antagonist, is an appropriate ligand for PE

96 or agonist, isoproterenol (ISO), or the beta-adrenoceptor antagonist, propranolol.

97 rats pretreated with atipamezole, an alpha2 adrenoceptor antagonist.

98 ere significantly reduced by alpha- and beta-adrenoceptor antagonists (-40%, p < 0.001 and -30%, p <

99 ulation of astrocytes was inhibited by alpha-adrenoceptor antagonists and abolished by depletion of n

100 beta-Adrenoceptor antagonists are used widely to reduce cardi

101 beta-Adrenoceptor antagonists boast a 50-year use for symptom

102 beta-Adrenoceptor antagonists differ in their degree of parti

103 Novel selective beta1-adrenoceptor antagonists for concomitant cardiovascular

104 Adrenoceptor antagonists or vehicle (5 ml/kg saline) was

105 , cimaterol) are potently inhibited by beta1-adrenoceptor antagonists, and 2) a low-affinity secondar

106 relatively resistant to inhibition by beta1-adrenoceptor antagonists.

107 ns containing oxymetazoline (OXY), an alpha1-adrenoceptor (AR) agonist of the imidazoline class.

108 have poor selectivity for the cardiac beta1-adrenoceptor (AR) over the lung beta2-AR.

109 sents approximately 25% of the total beta(2)-adrenoceptor (AR) population as determined with the anta

110 alpha(1)-Adrenoceptors are concentrated in the locus coeruleus (L

111 n the airways, muscarinic receptors and beta-adrenoceptors are expressed in different locations, indi

112 Adenosine receptors and beta-adrenoceptors are G-protein-coupled receptors (GPCRs) th

113 Muscarinic receptors and beta-adrenoceptors are physiological antagonists for smooth m

114 uture studies to better understand the beta3-adrenoceptor as a novel pharmacological target.

115 fied transmembrane region (TM)4 of the beta1-adrenoceptor as key for this low-affinity conformation.

116 Green Fluorescent Protein (GFP)-taggedbeta2 adrenoceptor at a slow rate, with half-life (t1/2) value

117 Thus, unlike at the human beta1-wild-type adrenoceptor, at beta1-TM4 mutant receptors, cimaterol a

118 Beta(2)-adrenoceptor (beta(2)-AR) agonists are very effective br

119 Chronic regular use of beta(2)-adrenoceptor (beta(2)-AR) agonists in asthma is associat

120 ked by a C9 polymethylene chain to a beta(2)-adrenoceptor (beta(2)AR) agonist moiety, represented by

121 the architecture of agonist-occupied beta(2)-adrenoceptor (beta(2)AR) in complex with the heterotrime

122 The beta(2)-adrenoceptor (beta(2)AR) was one of the first Family A G

123 es using knock-out mice suggest that beta(3)-adrenoceptor (beta(3)-AR) signaling is dependent on cave

124 hat certain beta-blockers, specifically beta-adrenoceptor (beta-AR) inverse agonists, may be useful i

125 ctivity (SNA) coupled with dysregulated beta-adrenoceptor (beta-AR) signaling is postulated as a majo

126 a condition characterized by excessive beta-adrenoceptor (beta-AR) stimulation.

127 udy, we examined the impact of AnxA4 on beta-adrenoceptor (beta-AR)/cAMP-dependent signal transductio

128 adiols mediate P-UAEC proliferation via beta-adrenoceptors (beta-AR) and independently of classic oes

129 ery endothelial cells (P-UAECs) through beta-adrenoceptors (beta-ARs) and independently of the classi

130 Anabolic beta2-adrenoceptor (beta2-AR) agonists have been proposed as t

131 beta2 adrenoceptor (beta2-AR)-agonists are used to relieve bro

132 sites into the C-terminal tail of the beta2-adrenoceptor (beta2AR) and demonstrate that this mutant,

133 Vps34 is required for recycling of the beta2-adrenoceptor (beta2AR), a prototypical GPCR, and then in

134 uch as adrenaline, which activates the beta2-adrenoceptor (beta2AR), bind with relatively low affinit

135 s simulations of lipid-embedded active beta2-adrenoceptor (beta2AR*) in complex with C-terminal pepti

136 acetylcholine receptors (mAChRs) and beta-2-adrenoceptors (beta2ARs) are important regulators of air

137 sustained activation of PKA induced by beta-adrenoceptor (betaAR) dictates signaling propagation for

138 l studies suggest that stress activates beta-adrenoceptors (betaARs) to enhance metastasis from prima

139 llenges in designing and validating targeted adrenoceptor-binding radiotracers, namely the heavily we

140 It was found that under systemic beta-adrenoceptor blockade (atenolol) combined with spinal co

141 mg x kg(-1)) or central nervous system beta1-adrenoceptor blockade (intracerebroventricular metoprolo

142 Central nervous system beta1-adrenoceptor blockade (metoprolol) did not reduce plasma

143 All trials occurred after local beta-adrenoceptor blockade (propranolol).

144 were performed during local alpha- and beta-adrenoceptor blockade (via a brachial artery catheter) t

145 Under beta-adrenoceptor blockade combined with spinal cord (C1) tra

146 Peripheral beta1-adrenoceptor blockade commenced 6 hrs after lethal endot

147 Chronic beta-adrenoceptor blockade disrupts this feedback system, lea

148 Peripheral beta1-adrenoceptor blockade offers anti-inflammatory and cardi

149 mygdala (BLA) to examine the effects of beta-adrenoceptor blockade on immediate and delayed extinctio

150 Peripheral beta1-adrenoceptor blockade through daily intraperitoneal inje

151 were performed during local alpha- and beta-adrenoceptor blockade to eliminate sympathoadrenal influ

152 beta-Adrenoceptor blockade with propranolol or inhibition of

153 We have shown that systemic beta-adrenoceptor blockade with propranolol rescues the IED,

154 pal D1/D5 receptor blockade and resistant to adrenoceptor blockade: memory enhancement and long-lasti

155 y of other combinations, for example, alpha1-adrenoceptor blocker and 5alpha-reductase inhibitor, has

156 Silodosin is the only adrenoceptor blocker that exhibits true selectivity for

157 patients with septic shock using the beta-1 adrenoceptor blocker, esmolol, with specific focus on sy

158 alpha1-Adrenoceptor blockers are the most frequently prescribed

159 wn that both antimuscarinic drugs and alpha1-adrenoceptor blockers can be useful for treatment of mal

160 Here, we tested the efficacy of mixed adrenoceptor blockers carvedilol and labetalol, and the

161 , combinations of antimuscarinics and alpha1-adrenoceptor blockers have produced the most promising r

162 nhibitors seems to be as effective as alpha1-adrenoceptor blockers in male lower urinary tract sympto

163 ast years new formulations of several alpha1-adrenoceptor blockers were introduced to the market.

164 this review is to highlight the evolution of adrenoceptor blockers with emphasis on newly approved dr

165 compounds exert their effects at the alpha2-adrenoceptor both in vitro in human prefrontal cortex ti

166 ments in inhaled corticosteroids and beta(2)-adrenoceptor bronchodilators.

167 reducing salmeterol's affinity for the beta2-adrenoceptor by 31-fold.

168 fter activation of adipocyte-expressed beta3 adrenoceptors by catecholamines, and identified eosinoph

169 in the BLA via an interaction with the beta-adrenoceptor-cAMP cascade, at a locus between the membra

170 nsolidation via an interaction with the beta-adrenoceptor-cAMP system in the BLA.

171 NDPK-C is a novel critical regulator of beta-adrenoceptor/cAMP signaling and cardiac contractility.

172 ll death, which is under the control of beta-adrenoceptor/cAMP/PKA axis through the regulation of PAR

173 aling and highlight the ability of the beta2-adrenoceptor/cAMP/PKA axis to rewire EphA2 signaling in

174 Prejunctional beta2-adrenoceptors can enhance neuronal acetylcholine release

175 rrently thought that activation of the beta2-adrenoceptor causes c-AMP dependent activation of PKA; h

176 At the beta1-adrenoceptor, CGP 12177 potently antagonizes agonist res

177 Wild-type beta2- and beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors, and r

178 affinity pharmacology of the secondary beta1-adrenoceptor conformation.

179 ole in the generation of the secondary beta1-adrenoceptor conformation.

180 rative interactions between 2 distinct beta1-adrenoceptor conformations.

181 anolol, respectively) and abolished in beta1-adrenoceptors containing TM4 mutations vital for the sec

182 with significant, regional-dependent alpha1 adrenoceptor cross-reactivity, limiting its potential us

183 showed that CUMI-101 had significant alpha1 adrenoceptor cross-reactivity.

184 nding techniques were used to measure alpha1-adrenoceptor density and the affinity of CUMI-101 for th

185 alpha1-adrenoceptor density and the affinity of CUMI-101 for th

186 Previously we reported on adrenoceptor-dependent sacral control of lumbar flexor m

187 rst, the ligand-recognition profile of beta3-adrenoceptors differs considerably from that of the othe

188 and parasympathetic nervous system, numerous adrenoceptor drugs were radiolabeled and potent radiolig

189 tween in vivo and in vitro measures of beta1-adrenoceptor efficacy (R(2)=0.93; P<0.0001).

190 Stimulation of alpha-adrenoceptors elicits vasoconstriction in resting skelet

191 The beta1-adrenoceptor exists in two agonist conformations/states:

192 P 12177 (BODIPY-TMR-CGP)] at the human beta1-adrenoceptor expressed in Chinese hamster ovary cells re

193 ity, associated with a restoration of alpha1-adrenoceptor expression in endotoxic shock.

194 d both mineralocorticoid receptor and alpha1-adrenoceptor expressions within 5 hours in human vascula

195 e (TM) regions of the human beta1- and beta2-adrenoceptors, followed by single point mutations, to de

196 ontrast, arrestin-3 interaction with a beta2-adrenoceptor fused to the carboxyl-terminal tail of the

197 tional deletion polymorphism in the alpha-2B adrenoceptor gene (ADRA2B) has been linked to emotional

198 at the 16 position (rs1042713) in the beta2-adrenoceptor gene (ADRB2) is associated with enhanced do

199 The role of beta3-adrenoceptor gene polymorphisms has insufficiently been

200 ause they represent attractive drug targets, adrenoceptors have been widely studied.

201 Recent structures of beta-adrenoceptors highlight residues in transmembrane region

202 s that negative cooperativity across a beta1-adrenoceptor homodimer may be responsible for generating

203 ciation rate were markedly enhanced in beta1-adrenoceptor homodimers constrained by bimolecular fluor

204 the development of a PET tracer for alpha2C adrenoceptor imaging and its preliminary preclinical eva

205 L/6J mice, pharmacologic activation of beta2 adrenoceptors improved the severity of shock, including

206 tic ganglia neurons and an increase of beta3-adrenoceptor in the SAT.

207 We show for the first time that adrenoceptors in anterior piriform cortex (aPC) must be

208 he maps of (11)C-yohimbine binding to alpha2 adrenoceptors in human brain had the highest values in c

209 he tracer (11)C-yohimbine for mapping alpha2 adrenoceptors in human brain in vivo.

210 mination of (11)C-CUMI-101 binding to alpha1-adrenoceptors in human cerebellum under in vivo conditio

211 These results indicate that beta2-adrenoceptors in regulatory lymphocytes are critical for

212 alpha2C adrenoceptors in the human brain may be involved in vari

213 nhanced expression and sensitivity of alpha2-adrenoceptors in the LC.

214 rough the use of X-ray data from ligand-beta-adrenoceptor (including ADRB1 and ADRB2) crystal structu

215 e and epinephrine by acting through specific adrenoceptors increase the synthesis of proangiogenic fa

216 )R with the agonist-bound structures of beta-adrenoceptors indicates that the contraction of the liga

217 Acute stimulation of cardiac beta-adrenoceptors is crucial to increasing cardiac function

218 Second, the expression pattern of beta3-adrenoceptors is more restricted than that of other subt

219 nding in wild-type and alpha2A- and alpha2AC adrenoceptor knockout (KO) mice.

220 hese amino acids to those found in the beta2-adrenoceptor (L195Q and W199Y), or mutation of a single

221 Third, beta3-adrenoceptors lack the phosphorylation sites involved in

222 p between structural properties of the beta2-adrenoceptor ligands and their interactions with membran

223 signaling pathways induced by different beta-adrenoceptor ligands.

224 moderate affinity (Ki = 6.75 nM) for alpha1 adrenoceptors measured in vitro.

225 These findings suggest that beta-adrenoceptors mediate stress-induced changes in mPFC spi

226 sms, that is, direct catecholamine toxicity, adrenoceptor-mediated damage, epicardial and microvascul

227 of 5-HT neurons revealed that, while alpha1-adrenoceptor-mediated excitation was unchanged, excitato

228 sions, BAY reversed both the attenuated beta-adrenoceptor-mediated inotropy and chronotropy.

229 Muscarinic agonism may attenuate beta-adrenoceptor-mediated relaxation more than other contrac

230 hibition are critically involved in alpha(1)-adrenoceptor-mediated vascular smooth muscle contraction

231 se cleavage-mediated) and reversible (alpha1 adrenoceptor-mediated) forms of channel activation.

232 nt of the ADRA2b gene coding for the alpha2b adrenoceptor modulates EEV in humans.

233 d an intense distribution of beta1-and beta2-adrenoceptor mRNA in the BLA.

234 ave its structure determined was the beta(1)-adrenoceptor mutant beta(1)AR-m23 bound to the antagonis

235 systems converge in the activation of beta2-adrenoceptors of splenic regulatory lymphocytes to contr

236 thers suggested that TM4 has a role in beta1-adrenoceptor oligomerization.

237 Importantly, the effect of beta3-adrenoceptor on mTOR complex 2 is independent of the cla

238 lates the activity of agonist-occupied beta1-adrenoceptors on a very fast time scale.

239 ia their binding to the active site of beta2-adrenoceptors on ASM, which triggers a signaling cascade

240 alcium-cAMP signaling by stimulating alpha2A-adrenoceptors on spines strengthens synaptic efficacy an

241 no effect on signaling and function of beta2-adrenoceptor or numerous procontractile GPCRs, but selec

242 from Tpcn2(-/-) mice showing no loss of beta-adrenoceptors or coupling mechanisms.

243 his article discusses three aspects of beta3-adrenoceptor pharmacology.

244 Here we show that activation of beta2-adrenoceptors promoted STD long-term synaptic potentiati

245 Immunohistochemistry revealed beta(1)-adrenoceptor protein on sympathetic axon terminations.

246 agonism of the P2X1-purinoceptor and alpha1A-adrenoceptor provides a safe and effective therapeutic t

247 atic analysis, and the inability of targeted adrenoceptor radioligands to have an impact on clinical

248 ion of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substitution of

249 Adrenoceptors receptors (ARs) play a pivotal role in reg

250 r antagonism of D1, 5HT1A, or alpha- or beta-adrenoceptors, reproduced the profile of DAMGO effects.

251 ine the exact amino acids in the human beta2-adrenoceptor responsible for this very high selectivity.

252 rmine the key residues involved in the beta1-adrenoceptor secondary conformation.

253 t prazosin, and are mimicked by the alpha(1)-adrenoceptor-selective agonist phenylephrine.

254 th wash, are largely blocked by the alpha(1)-adrenoceptor-selective antagonist prazosin, and are mimi

255 ile afforded 19, a ligand with similar beta1-adrenoceptor selectivity and partial agonism (log KD of

256 In vitro beta-adrenoceptor selectivity and partial agonism of 19 were

257 The alpha2C adrenoceptor selectivity of the tracer was determined by

258 This unique adrenoceptor selectivity profile likely accounts for the

259 pe mice selectively increased (40-60%) beta2-adrenoceptor signaling and function.

260 ampal synaptic plasticity by activating beta-adrenoceptor signaling and mitigating synaptotoxicity of

261 dent responses were mainly mediated by beta1-adrenoceptor signaling in TTS.

262 in peripheral, as well as central, alpha(2)-adrenoceptor signaling oppose the behavioral stimulant e

263 tion mediated via canonical beta1- and beta2-adrenoceptor signaling pathways; and (5) evidence for ad

264 ein LMBRD2 as a potential regulator of beta2 adrenoceptor signaling, underscoring the value of a dyna

265 We show that beta3-adrenoceptors stimulate glucose uptake in brown adipose

266 n (mTOR) complex 2 has a novel role in beta3-adrenoceptor-stimulated glucose uptake in brown adipose

267 Both parts are essential for beta3-adrenoceptor-stimulated glucose uptake.

268 By contrast, alpha(2)-adrenoceptor stimulation evokes finger vasoconstriction

269 constriction evoked by extraluminal alpha(1)-adrenoceptor stimulation is blunted by vasodilator COX p

270 Under submaximal beta-adrenoceptor stimulation of brown adipocytes, a PDE3 inh

271 Prolonged beta1-adrenoceptor stimulation suppresses IKs by downregulatin

272 antagonists are available for the human beta-adrenoceptor subtype involved in these diseases, yet few

273 The expression and characteristics of beta-adrenoceptor subtypes (beta1 and beta2) and their agonis

274 a docking study at the alpha2A- and alpha2C-adrenoceptor subtypes demonstrating the structural featu

275 file at both 5-HT(1A) receptors and alpha(1)-adrenoceptor subtypes was measured by binding assay and

276 hat exhibits true selectivity for the alpha1-adrenoceptor subtypes.

277 Structural modeling of the human beta1-adrenoceptor suggested interaction of the side chain of

278 human cerebellum reflects binding to alpha1-adrenoceptors, suggesting that the cerebellum is of limi

279 a hyperfunctional variant of the human beta1-adrenoceptor that carries an arginine at position 389 in

280 The pathway involves activation of beta2-adrenoceptors that increase cAMP levels and activate cAM

281 Desensitization of beta2-adrenoceptors that occurs during the first few days of r

282 , is an appropriate ligand for PET of alpha2 adrenoceptors that passes readily from blood to brain ti

283 neering phosphorylation sites into the beta2-adrenoceptor the receptor showed prolonged interaction w

284 a single residue (W199D) in the human beta1-adrenoceptor thus abolished this secondary conformation

285 centration response at human beta1-wild-type adrenoceptors to a monophasic concentration response in

286 pathways linking chronic stimulation of beta-adrenoceptors to hypertrophy and associated arrhythmias.

287 e observed with cardiomyocyte-specific beta1-adrenoceptor transgenic mice and human heart biopsies.

288 igated the effects of blocking 5-HT and beta-adrenoceptor transmission in DH on drug seeking during E

289 These findings indicate that alpha2-adrenoceptors trigger signals that protect the integrity

290 quantify the density and affinity of alpha 2 adrenoceptors under condition of changing radioligand bi

291 force, MLCK FRET ratio activated by alpha(1)-adrenoceptors was approximately 60% of that activated by

292 ificity of (11)C-ORM-13070 binding to alpha2 adrenoceptors was demonstrated in rats pretreated with a

293 The cross-reactivity of CUMI-101 with alpha1 adrenoceptors was performed using in vitro radioligand b

294 Their target, the beta3-adrenoceptor, was discovered much later than beta1- and

295 2 inhibition by norepinephrine (via alpha(2)-adrenoceptors, which do not bind NHERF2), nor on Ca(V)2.

296 duction of in vitro affinity at the alpha(1)-adrenoceptor while both potency and efficacy were increa

297 h factor receptor (EGFR) with EGF, the beta2-adrenoceptor with dopamine, or the hepatocyte growth fac

298 s secondary conformation and created a beta1-adrenoceptor with only one high-affinity agonist conform

299 -fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or selectiv

300 y differs between the human and rodent beta3-adrenoceptor, yielding considerable species differences